ERBB2 and breast cancer: In this study, we have shown that high MBD is associated with a superior prognosis compared to low MBD, and that MBD is a strong independent prognostic factor in operable primary invasive female breast cancer, especially in patients older than 50 years and with the HRc(+)/HER2(−) subtype.